The St. Louis Division

DEA St. Louis Field Division and Its Diversion-Control System

Last fully verified: July 25, 2026

Executive Finding

The Drug Enforcement Administration’s St. Louis Division is the regional DEA command responsible for Missouri, Kansas, and at least the southern portion of Illinois.

The exact public description of that territory is inconsistent.

DEA’s live St. Louis Division page states that the division serves:

Illinois
Kansas
Missouri

A current DEA leadership announcement dated July 6, 2026, describes the division more narrowly as operating through ten offices across:

Kansas
Missouri
Southern Illinois

Other DEA materials also describe the territory as Kansas, Missouri, and southern Illinois. Meanwhile, DEA’s live Chicago Division page independently states that the Chicago Division serves Illinois, Indiana, and Wisconsin.

These official descriptions cannot all be read literally without creating an unexplained overlap across Illinois.

The most defensible conclusion is:

The St. Louis Division unquestionably serves all of Missouri and Kansas and exercises responsibility in southern Illinois. DEA’s current public materials do not provide a precise county-by-county boundary explaining where St. Louis Division responsibility ends and Chicago Division responsibility begins.

Seeds of Vice does not silently assign the entire state of Illinois to either division.

The division’s office network is comparatively clear. DEA currently identifies the St. Louis headquarters and nine subordinate field locations, producing the ten-office structure referenced in the July 2026 leadership announcement.

Its diversion-control command structure is less transparent.

DEA publicly identifies:

The Special Agent in Charge
Headquarters and field-office locations
General telephone numbers
A community-outreach contact
A recruitment contact
A regional Diversion Outreach telephone number and email address

DEA does not currently publish:

The name of the division’s Diversion Program Manager
A diversion-control organizational chart
The supervisory chain for Missouri, Kansas, and southern Illinois
The number or placement of Diversion Investigators
Division-level registration statistics
Inspection and compliance totals
Administrative-action totals
Processing times
Patient continuity-of-care measurements

The public can therefore identify the division’s general leadership and geography, but it cannot fully examine the regional federal system governing lawful controlled substances.

Who the St. Louis Division Serves

The St. Louis Division operates across a territory containing two complete states and an undefined portion of a third.

Its regional responsibilities include major metropolitan areas, smaller industrial cities, agricultural communities, remote western Kansas counties, Missouri’s Ozark region, the Kansas City metropolitan area, the St. Louis metropolitan area, and communities across southern Illinois.

The region contains:

Physicians
Dentists
Pharmacies
Hospitals
Veterinarians
Researchers
Manufacturers
Distributors
Narcotic treatment programs
Institutional practitioners
Other DEA registrants

It also contains millions of patients whose access to controlled medication depends upon the continued legal operation of those registrants.

DEA’s authority is federal. Healthcare delivery, professional licensure, pharmacy regulation, prescription-monitoring requirements, and treatment availability remain substantially state-based.

The result is one regional DEA command operating across three different state regulatory environments.

The Illinois Jurisdiction Conflict

What DEA’s Live Division Pages State

DEA’s current St. Louis page uses the heading:

Serving Illinois, Kansas and Missouri

DEA’s current Chicago page states that the Chicago Division serves:

Illinois
Indiana
Wisconsin

Read literally, both pages claim Illinois.

What DEA’s Current Leadership Announcement States

When Steven L. Hofer was appointed Special Agent in Charge in July 2026, DEA stated that he would oversee operations across ten offices in:

Kansas
Missouri
Southern Illinois

The announcement did not say that the St. Louis Division serves all of Illinois.

What the Office List Suggests

DEA lists two Illinois field locations under the St. Louis Division:

Carbondale
Fairview Heights

Both are in southern Illinois.

No northern or central Illinois office is listed under St. Louis. The placement of the listed offices is consistent with the narrower “southern Illinois” description, but office locations alone do not establish an exact legal boundary.

What Can Be Concluded

The evidence supports the following conclusions:

Missouri belongs to the St. Louis Division.
Kansas belongs to the St. Louis Division.
Southern Illinois is within the St. Louis Division’s operational territory.
DEA’s live St. Louis summary page uses broader statewide Illinois language.
DEA’s live Chicago page also claims Illinois.
DEA has not provided an accessible county-level jurisdictional explanation resolving the overlap.

What Cannot Be Concluded

The public materials reviewed do not establish:

The exact Illinois counties assigned to St. Louis
The precise boundary between the St. Louis and Chicago divisions
Whether responsibility is divided by county, judicial district, office function, case type, or another administrative arrangement
Whether the broad statewide headings are merely website shorthand
Whether one of the live pages is outdated or overinclusive

The conflict is itself a finding.

It should not be corrected through assumption.

Territory and Office Structure

DEA’s current public materials identify ten St. Louis Division offices: the headquarters and nine additional field locations.

Division Headquarters

DEA St. Louis Division
317 South 16th Street
St. Louis, Missouri 63103

Main telephone: (314) 538-4600

Illinois Field Locations

Carbondale

Telephone: (618) 457-3605

Fairview Heights

Telephone: (618) 628-0025

Kansas Field Locations

Garden City

Telephone: (620) 275-7798

Kansas City

Telephone: (913) 951-4000

Topeka

Telephone: (785) 232-4065

Wichita

Telephone: (316) 838-2500

Missouri Field Locations

Cape Girardeau

Telephone: (573) 334-1534

Jefferson City

Telephone: (573) 635-1331

Springfield

Telephone: (417) 888-9800

DEA’s public office list therefore consists of:

One headquarters
Two listed Illinois locations
Four Kansas locations
Three additional Missouri locations

Together, these form the ten-office network described in DEA’s July 2026 leadership announcement.

Office Classifications

DEA displays a legend using the following terms:

Division Office
District Office
Resident Office
Post of Duty Office

The accessible public text does not clearly and consistently associate every listed city with one of those classifications.

Accordingly, Seeds of Vice describes them as DEA-listed field locations unless DEA expressly identifies the office type.

No classification has been inferred from:

City size
Telephone number
Geographic importance
Historical office descriptions
Assumed staffing levels

What Is Not Published

The office list does not disclose:

Which offices contain Diversion Investigators
Which offices process registration matters
Which offices conduct regulatory inspections
Whether diversion personnel are assigned permanently to all three states
Which office supervises each Illinois county
Whether any locations are enforcement-only
How diversion cases are distributed among the offices
The number of personnel at each location

A location appearing on the field-division page does not establish that every DEA function is available there.

The Name Matters

The St. Louis Field Division is not the national Diversion Control Division.

The St. Louis Division is a regional DEA command. It performs criminal enforcement, intelligence, administrative, community-outreach, and diversion-related functions throughout its assigned territory.

The national Diversion Control Division administers major parts of DEA’s nationwide regulatory system governing controlled pharmaceuticals and listed chemicals.

Regional Diversion Investigators operate within this larger national structure.

The accurate description is therefore:

DEA St. Louis Field Division and its diversion-control system

It is not a separate federal entity formally called the “St. Louis Diversion Division.”

Current Leadership and Publicly Identified Personnel

Steven L. Hofer

Special Agent in Charge

Steven L. Hofer is the current Special Agent in Charge of the St. Louis Field Division.

DEA announced his appointment on July 6, 2026. The agency stated that Hofer oversees enforcement, intelligence, diversion, and administrative operations across ten offices in Kansas, Missouri, and southern Illinois.

Hofer joined DEA in 2004 after more than ten years in the United States Army. DEA states that he commanded a company in Ramadi, Iraq, and received the Bronze Star.

His prior DEA assignments include:

The St. Louis Division’s Violent Traffickers Task Force
Group supervision in Springfield, Missouri
DEA headquarters work involving national initiatives directed at pharmaceutical opioid manufacturers and distributors
Service as an Assistant Special Agent in Charge in Baton Rouge
Service as Special Agent in Charge of the New Orleans Division

DEA states that, while leading the New Orleans Division, Hofer was responsible for more than 600 employees operating across Alabama, Arkansas, Louisiana, and Mississippi.

He holds an undergraduate degree in business marketing with a minor in military science from Missouri Western State University and a master’s degree in criminology and criminal justice from the University of Missouri–St. Louis.

Hofer succeeded Michael A. Davis.

Significance for Diversion Control

Hofer’s current official biography expressly places diversion operations within his division-wide command responsibility.

His biography also identifies headquarters experience involving pharmaceutical opioid manufacturers and distributors. That experience is relevant to diversion-control administration, but it does not establish the division’s current internal diversion hierarchy or identify who manages the program’s daily regional operations.

Publicly Identified Support Contacts

Community Outreach

Dan Plumb

Telephone: (571) 362-7591
Email: STLDiv.PublicAffairs@dea.gov

Recruitment

Special Agent Chris Most

Telephone: (314) 538-4600
Email: StLouisSpecialAgentRecruiter@dea.gov

Media Inquiries

Telephone: (571) 362-5149

Diversion Outreach

Telephone: (571) 387-5067
Email: StLouisDiversionOutreach@dea.gov

These contacts appear on DEA’s current St. Louis Division page.

The Diversion Outreach contact is a regional public point of contact. DEA does not describe it as the direct telephone line for a particular Diversion Investigator, supervisor, enforcement group, or registration adjudicator.

Current Diversion Leadership Is Not Publicly Named

The live St. Louis Division page does not identify a current Diversion Program Manager.

The most recent official DEA materials located during this review publicly named Kimberly “Kim” Daniels as the Diversion Program Manager responsible for Missouri, Kansas, and southern Illinois. Those materials were published in 2023 and 2024.

Because no current 2026 DEA source located for this page confirms that Daniels still holds the position, Seeds of Vice does not present her as the current manager.

Her last verified public role should be described as:

Kimberly “Kim” Daniels — publicly identified by DEA as the regional Diversion Program Manager in official materials published through 2024; current status not established by the live 2026 division page.

That distinction prevents an older official identification from being silently converted into a current personnel claim.

Publicly Unidentified Positions

DEA does not currently identify:

The current Diversion Program Manager
Deputy or assistant diversion managers
Diversion group supervisors
The official responsible for Kansas
The official responsible for Missouri
The official responsible for southern Illinois
Tactical Diversion Squad supervisors
Registration-program supervisors
Diversion personnel assigned to individual field offices
Diversion-focused public-information personnel

The absence of names does not prove that the positions are vacant.

It means the personnel structure is not publicly visible.

Official Role and Mission

DEA states that the national Diversion Control Division exists to prevent, detect, and investigate the movement of controlled pharmaceuticals and listed chemicals from legitimate sources into unlawful traffic while also ensuring an adequate and uninterrupted supply for legitimate medical, scientific, and commercial needs.

The mission contains two obligations:

Protect the lawful system from theft, fraud, falsification, unlawful prescribing, improper dispensing, and other forms of diversion.
Preserve an adequate and uninterrupted supply for legitimate use.

Both obligations matter.

A complete assessment cannot measure diversion control only through:

Arrests
Search warrants
Convictions
Civil penalties
Registration surrenders
Suspensions
Revocations
Reduced dispensing

It must also examine whether lawful patients, practitioners, hospitals, pharmacies, veterinarians, researchers, manufacturers, and distributors retain workable access to the controlled substances they legitimately require.

The Closed System of Distribution

Federal controlled-substance law establishes a regulated distribution system extending from production and distribution through prescribing and dispensing.

Participants may include:

Manufacturers
Distributors
Importers
Exporters
Pharmacies
Hospitals
Physicians
Dentists
Veterinarians
Researchers
Narcotic treatment programs
Mid-level practitioners where authorized
Other institutional and individual registrants

DEA registration generally authorizes specified activities involving specified schedules of controlled substances.

Registration does not replace state authorization.

A practitioner may require:

A state professional license
State controlled-substance authority
DEA registration
Institutional credentials
Compliance with state prescription-monitoring requirements
Compliance with employer, insurer, hospital, or pharmacy policies

A person may therefore possess federal registration but lack state authority, or possess state licensure but lack the necessary federal registration.

Federal Regulatory Responsibilities

Depending on registrant type, the system may govern:

Initial registration
Renewal
Registration modification
Authorized schedules
Recordkeeping
Inventories
Ordering
Transfers
Storage
Physical security
Theft and significant-loss reporting
Prescription issuance
Dispensing
Disposal
Employee access
Automated dispensing systems
Suspicious orders
Registration surrender
Suspension or revocation

Diversion control is broader than investigating physicians.

It reaches the entire lawful channel.

Traditional Regional Diversion-Control Work

Regional diversion activity may include:

Reviewing registration applications
Conducting regulatory inspections
Auditing controlled-substance inventories
Examining purchasing and dispensing records
Investigating thefts and significant losses
Investigating employee diversion
Reviewing suspicious-order practices
Examining prescription legitimacy
Investigating forged or altered prescriptions
Reviewing institutional security
Examining automated dispensing records
Coordinating with state licensing authorities
Coordinating with prescription-monitoring programs
Negotiating corrective agreements
Seeking civil penalties
Requesting or accepting registration surrender
Recommending administrative action
Supporting criminal investigations
Referring evidence to federal prosecutors

Not every inspection becomes an investigation.

Not every regulatory deficiency is criminal.

Not every settlement establishes that all government allegations were proven.

Not every registration surrender is an admission to a criminal offense.

Legal posture must be preserved matter by matter.

Broader Drug Enforcement Is Not the Same as Diversion Control

The St. Louis Division also investigates:

Fentanyl trafficking
Methamphetamine distribution
Cocaine distribution
Heroin trafficking
Drug-trafficking organizations
Cartel-linked activity
Money laundering
Firearms associated with drug trafficking
Pharmacy burglaries and illicit resale
Interstate distribution networks

Those operations are part of DEA’s broader criminal-enforcement mission.

They should not automatically be counted as diversion-control activity.

For example:

A fentanyl seizure does not reveal how many registrants were inspected.
A cocaine prosecution does not measure registration-processing time.
A cartel investigation does not establish whether legitimate medical supply remained adequate.
A pharmacy burglary may involve controlled drugs, but it does not by itself establish regulatory misconduct by the pharmacy.

The illicit market and the lawful regulated channel can intersect. They remain analytically distinct.

How the System Works in Practice

Registrants

A registrant operating within the St. Louis Division may answer to several authorities simultaneously:

DEA
State medical, dental, nursing, veterinary, or pharmacy boards
State controlled-substance agencies
State prescription-monitoring programs
State health departments
Federal and state prosecutors
Hospitals and credentialing bodies
Insurers
Pharmacy chains
Institutional compliance departments

When prescribing or dispensing changes, responsibility may be distributed among several institutions.

A treatment interruption should not automatically be attributed solely to DEA.

A decline in prescribing may result from:

Federal investigation
State-board action
State law
Prescription-monitoring requirements
Insurer limits
Hospital policy
Pharmacy policy
Supply shortages
Clinical guidelines
Corporate risk management
Practitioner judgment
Fear of regulatory scrutiny

Determining causation requires more than observing that the decline occurred.

Prescribers

Federal law requires controlled-substance prescriptions to be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.

That federal standard interacts with state law and professional regulation.

Prescribers may also be expected to consider:

Patient history
Examination and diagnosis
Prescription-monitoring information
Medication combinations
Dosage and duration
Prior treatment
Documented treatment objectives
Signs of misuse or diversion
Follow-up and monitoring
State-specific requirements

The existence of a prescription does not prove that it was legitimate.

The existence of a high dosage does not independently prove that it was illegitimate.

The legitimacy of an individual prescription depends upon the applicable law, professional practice, patient circumstances, and evidence.

Pharmacists

Pharmacists have independent legal and professional responsibilities.

They may evaluate:

Whether the prescription appears valid
Whether the prescriber is authorized
Whether the prescription was altered
Refill timing
Drug combinations
Dosage
Quantity
Geographic distance
Patient identification
Payment method
Multiple-prescriber or multiple-pharmacy patterns
Other warning signs

A pharmacist may refuse to dispense even when a prescriber considers the prescription medically appropriate.

That refusal may result from:

Federal or state law
Professional judgment
Corporate policy
Insurer requirements
Inventory limitations
Supply-chain restrictions
Concern about regulatory exposure

The public record rarely identifies which factor controlled a particular refusal.

Hospitals and Institutional Registrants

Hospitals and other institutions must maintain systems capable of detecting and responding to controlled-substance discrepancies.

Institutional controls may include:

Inventory reconciliation
Restricted employee access
Automated dispensing-cabinet monitoring
Wastage documentation
Override review
Discrepancy investigation
Surveillance
Theft-and-loss reporting
Employee testing or assessment where lawful
Referral to licensing and law-enforcement authorities

Diversion within a hospital can harm:

The institution
The employee involved
Patients who receive diluted, substituted, or missing medication
The public if stolen medication enters illicit channels

Regulatory oversight in this setting has a clear patient-safety function.

Veterinarians

Veterinary practitioners and facilities are also part of the controlled-substance system.

Their responsibilities may include:

Secure storage
Accurate inventory
Documentation of administration
Proper prescribing
Employee-access controls
Theft reporting
Disposal
Protection against diversion involving animal patients

The fact that the patient is an animal does not remove the drugs from federal regulation.

The Three State-Control Layers

The St. Louis Division applies one federal statutory framework across three state systems.

Kansas

Kansas operates the K-TRACS Prescription Drug Monitoring Program through the Kansas Board of Pharmacy.

The program is intended to provide authorized healthcare professionals with controlled-substance dispensing information that may assist clinical decision-making and patient safety. Kansas separately regulates who must report dispensing information and how authorized users may obtain access.

K-TRACS is a Kansas state system.

It should not be described as a database created or exclusively controlled by the DEA St. Louis Division.

Kansas practitioners and pharmacies remain subject to independent state licensing and professional requirements in addition to federal registration.

Missouri

Missouri’s statewide Prescription Drug Monitoring Program operates under a Joint Oversight Task Force.

The current program collects information concerning prescribed Schedule II, III, and IV controlled substances submitted by Missouri dispensers. Authorized Missouri healthcare providers may use the information when evaluating prescription histories.

Missouri’s system differs from many other state programs in important respects.

Current program materials state that:

Access is limited to qualifying Missouri-licensed or authorized healthcare providers.
Interstate sharing is not permitted under the governing state statute.
Individually identifiable dispensing information is protected.
Law-enforcement and prosecutorial access is restricted by state law.
Publicly released research or statistical data must remove identifying information.

The program publishes quarterly public dashboards, including a 2026 first-quarter dashboard. Those public reports can provide state-level context but do not reveal the St. Louis Division’s internal investigative use, registration workload, or enforcement decisions.

Missouri’s PDMP and DEA’s registration system are separate institutions.

Illinois

Illinois operates the Illinois Prescription Monitoring Program through the Illinois Department of Public Health.

The program collects dispensing information involving Schedule II through V controlled substances. Illinois requires covered pharmacies to report qualifying dispensing information, and state law imposes checking or documentation duties in specified prescribing circumstances.

The Illinois PMP is statewide.

The DEA St. Louis Division, however, appears to exercise operational responsibility only in southern Illinois, notwithstanding the broader language on its live division page.

Therefore:

Statewide Illinois PMP data cannot automatically be treated as St. Louis Division data.
Northern and central Illinois activity may involve the Chicago Division.
Any regional analysis must avoid assigning the whole Illinois dataset to St. Louis.

Cross-State Complications

The division’s three state systems are not interchangeable.

Differences may include:

Which substances are reported
Who may access the database
Whether interstate sharing is allowed
How long data are retained
Whether prescribers must check
Which exceptions apply
Whether law enforcement may obtain direct access
What legal process is required
How veterinary prescriptions are treated
How delegates and institutional users are authorized

A multistate federal division must operate without pretending those state systems are identical.

Missouri’s prohibition on interstate sharing is particularly important. A regional DEA command does not automatically convert three state databases into one unified regional record.

Diversion Control and Lawful Medicine

The need for diversion control is real.

Controlled substances can be:

Stolen from pharmacies or hospitals
Diverted by employees
Obtained through forged prescriptions
Prescribed without lawful medical purpose
Dispensed despite unresolved warning signs
Purchased through fraudulent identities
Removed from veterinary facilities
Concealed through false inventories
Distributed outside authorized channels

The St. Louis Division’s record contains examples of several of these forms of misconduct.

The need for legitimate access is also real.

Controlled substances are used in:

Surgery
Emergency care
Anesthesia
Cancer treatment
Palliative care
Hospice
Acute-pain treatment
Chronic-pain treatment
Mental-health treatment
Addiction treatment
Veterinary medicine
Research

DEA’s own national mission expressly includes maintaining an adequate and uninterrupted legitimate supply.

That obligation does not prevent lawful enforcement.

It means enforcement and access must both be measured.

What Is Not Publicly Measured

The public record reviewed for this page does not show whether the St. Louis Division systematically measures:

Patients who lose access after a registration action
Patients displaced when a clinic closes
Patients affected by pharmacy restrictions
Whether records are transferred
Whether patients receive notice
Whether alternate prescribers are available
Whether rural communities retain local treatment
Whether a hospital action disrupts medication continuity
Whether abrupt discontinuation occurs
Whether pain or palliative-care patients are separately evaluated
Whether registrants receive technical correction before punitive action
Whether legitimate supply remained adequate after an intervention

The absence of published measurements does not prove that DEA performs no internal review.

It establishes that the public cannot evaluate that review.

Prescribing Statistics Without False Continuity

Seeds of Vice uses 1984 as the historical starting point for examining the transformation of lawful medicine.

That does not mean one continuous, comparable dataset exists from 1984 through 2026.

It does not.

No defensible public source located for this page provides an annual, same-definition, state-by-state retail opioid-dispensing series for Missouri, Kansas, and the St. Louis Division’s portion of Illinois beginning in 1984.

Accordingly:

Missing years are not interpolated.
Statewide Illinois figures are not assigned exclusively to St. Louis.
Prescription counts are not treated as dosage measurements.
Prescriptions per 100 residents are not treated as MME per capita.
Retail dispensing is not treated as total medical utilization.
Overdose deaths are not treated as prescribing rates.
State trends are not described as DEA performance statistics.
Different datasets are not joined into a false continuous line.

1984–2005

For this period, the historical record must be assembled from separate evidence, including:

Federal controlled-substance policy
DEA registration and regulatory history
National pharmaceutical distribution
Medical practice
Drug-utilization research
State laws
Professional guidance
Later retrospective datasets

These sources can establish historical conditions and institutional change.

They do not create a continuous St. Louis Division dispensing rate.

Seeds of Vice does not manufacture missing annual state values.

2011 State Benchmark

CDC’s archived state retail-dispensing estimates report the following 2011 opioid prescription rates:

State	Opioid prescriptions per 100 residents
Illinois	64.3
Kansas	87.8
Missouri	91.6

These were statewide estimates.

The Illinois figure includes areas outside the St. Louis Division’s apparent southern Illinois territory. It therefore cannot be used as a direct measurement of the division.

The figures also do not reveal:

How many individual patients received medication
The average dose
Duration of treatment
Diagnosis
Whether the prescription was medically appropriate
Whether medication was diverted
Whether patients were adequately treated
Whether changes resulted from DEA action
Whether state rules, insurers, hospitals, pharmacies, or clinical practice caused later declines

A prescription rate measures dispensing volume under a defined methodology.

It does not decide the legitimacy of individual treatment.

Current National Retail Series

CDC reports that the national retail opioid-dispensing rate declined from:

46.8 prescriptions per 100 persons in 2019
To 35.4 prescriptions per 100 persons in 2024

That represents a decline of approximately 24.4 percent over the period.

CDC states that the estimates are based on IQVIA Xponent information from approximately 54,600 nonhospital retail pharmacies representing nearly 94 percent of United States retail prescriptions.

The methodology excludes:

Mail-order prescriptions
Methadone dispensed through opioid treatment programs

Geography is generally assigned according to the prescriber’s location rather than the patient’s residence.

These limitations are material.

The figures do not measure:

All hospital administration
All institutional use
All opioid treatment
All patient exposure
All dosage
All pain treatment
Whether an individual prescription was justified
Whether a patient retained continuity of care

What the Prescribing Evidence Establishes

The defensible conclusion is limited:

Retail opioid dispensing has declined substantially from the higher levels documented during the early twenty-first century.

The evidence does not independently establish:

Why every decline occurred
Whether the St. Louis Division caused it
Whether every reduction improved care
Whether every discontinued prescription was unnecessary
Whether diversion declined proportionately
Whether pain prevalence declined
Whether undertreatment increased
Whether patients moved toward illicit substances
Whether pharmacies became more restrictive
Whether clinicians became more accurate or simply more fearful

Prescribing volume is an important indicator.

It is not a complete measure of medical justice.

Illicit-Market and Overdose Context

The present illicit drug environment must be kept separate from the retail-prescription record.

CDC states that prescription opioids remain involved in overdose deaths but are not the primary current driver of the national opioid-overdose crisis. Illicitly manufactured fentanyl and related synthetic opioids now account for a large portion of opioid deaths.

That distinction does not establish that lawful prescribing is risk-free.

It establishes that:

Retail prescriptions
Illicit fentanyl
Heroin
Counterfeit tablets
Polysubstance use
Pharmaceutical diversion

are different analytical categories.

A seizure of illicit fentanyl should not be used as a direct measurement of lawful prescribing.

A decline in retail prescriptions should not automatically be credited with reducing illicit-market harm.

A rise in illicit deaths does not, by itself, prove that prescribing reductions caused those deaths.

Causation requires evidence.

Representative Diversion-Control Matters

The following matters illustrate the types of cases arising within the St. Louis Division’s territory.

They are not a complete list, a random sample, or a division-wide performance measure.

Kansas and Missouri Nurse

Guilty plea and criminal sentence

In July 2026, DEA reported that a Missouri nurse was sentenced after pleading guilty to obtaining controlled substances through deception and subterfuge.

According to the official account, she used a nurse practitioner’s prescription pad and DEA registration number to create fraudulent prescriptions for Percocet and oxycodone. She admitted responsibility for thirteen fraudulent prescriptions involving medication obtained in Kansas and Missouri.

The court imposed:

Three years of probation
A $5,000 fine

The case also resulted in the loss of her nursing license and permanent exclusion from federal healthcare programs. DEA investigated the matter.

This was not merely an unresolved allegation.

It involved a guilty plea and criminal sentence.

The case illustrates:

Misuse of another practitioner’s DEA registration
Forged prescriptions
Cross-state acquisition
Diversion by a healthcare professional
Coordination between criminal and professional consequences

Olathe, Kansas, Pharmacy

Civil settlement of allegations

In 2023, Four B Corporation, operating a Price Chopper pharmacy in Olathe, Kansas, agreed to pay $250,000 to settle federal Controlled Substances Act allegations.

The government alleged that the pharmacy:

Dispensed controlled substances before receiving valid prescriptions
Improperly completed partial fills
Failed to maintain required inventory records

The allegations concerned conduct occurring between February 2019 and June 2022. DEA investigated the matter.

This was a civil settlement.

The settlement resolved asserted government claims. It should not be rewritten as a criminal conviction or as a jury finding that every allegation was proven.

The case illustrates the regulatory side of diversion control:

Prescription documentation
Partial-fill requirements
Inventory accountability
Pharmacy compliance
Civil monetary resolution

St. Louis-Area Physician

Guilty pleas and imprisonment

In September 2025, a federal court sentenced Dr. Asim Muhammad Ali to 70 months in prison.

The official record states that Ali had admitted involvement in healthcare fraud, illegal controlled-substance prescribing, kickbacks, and later conduct involving another physician’s DEA registration and ketamine-related operations.

The government described prescriptions issued without legitimate medical need, prescriptions prepared without appropriate patient visits, and conduct involving patients believed to be diverting medication. DEA participated in the investigation.

This matter involved guilty pleas and a criminal sentence.

It should not be described merely as an accusation.

The case also demonstrates that one investigation can involve:

Controlled-substance law
Healthcare fraud
Registration misuse
Billing misconduct
Professional authority
Multiple federal investigative agencies

Saint Francis Medical Center

Civil settlement concerning institutional responsibility

Saint Francis Medical Center in Cape Girardeau agreed to pay approximately $1.625 million to resolve federal Controlled Substances Act allegations connected to opioid prescriptions attributed to a physician associated with the institution.

The settlement also required the creation of an opioid-prescribing education foundation. DEA, the Department of Health and Human Services Office of Inspector General, and Missouri authorities participated in the investigation.

This was a civil settlement of government allegations.

It was not a criminal conviction of the medical center.

The matter illustrates that federal scrutiny may extend beyond the individual prescriber to an institution’s:

Oversight
Compliance systems
Employment relationships
Billing
Credentialing
Response to prescribing practices

Southern Illinois Pharmacy Burglaries

Indictment and unresolved charges

In May 2026, federal authorities announced charges against four defendants accused of participating in a multistate pharmacy-burglary conspiracy.

The indictment included burglaries or attempted burglaries involving pharmacies in southern Illinois communities including:

Bethalto
Maryville
Lebanon
Breese
Neoga

DEA participated in the investigation.

These were charges contained in an indictment.

The defendants are presumed innocent unless proven guilty.

The case illustrates an important distinction:

The controlled substances originated in lawful pharmacies.
The alleged diversion occurred through outside criminal theft.
The existence of stolen medication does not necessarily establish wrongdoing by the affected pharmacies.

Diversion control must be capable of distinguishing registrant misconduct from registrant victimization.

What the Representative Matters Show

The cases establish that controlled substances may leave lawful channels through:

Forged prescriptions
Misuse of another person’s DEA registration
Healthcare-professional diversion
Recordkeeping failures
Improper dispensing
Institutional oversight failures
Unlawful prescribing
Outside burglary and theft

They do not establish how frequently those events occur among all registrants.

DEA and DOJ press releases are selected case announcements.

They do not reveal:

The total number of registrants
The number inspected
The number found compliant
The number receiving technical assistance
The number of complaints found unsubstantiated
The number of investigations closed without action
The number of administrative cases contested
The number dismissed
The number of patients affected
The average duration of investigations
The frequency of corrective action compared with punishment

A collection of successful cases proves that cases exist.

It does not describe the complete regulatory system.

Legal Posture Must Be Preserved

The following categories are not interchangeable:

Allegation

A government agency asserts that conduct occurred.

Indictment or charge

A prosecutor formally accuses a person or entity. Guilt has not been established.

Guilty plea

A defendant admits guilt to an offense in court.

Conviction

Guilt has been established through a plea or verdict.

Criminal sentence

A court imposes punishment after conviction.

Civil settlement

Parties resolve civil claims, often without litigating every allegation to judgment.

Administrative action

DEA or another regulator acts against a registration, license, or authorization through an administrative process.

Voluntary surrender

A registrant relinquishes an authorization. The surrender may occur under pressure or as part of an agreement, but it is not automatically a criminal conviction.

Dismissal or acquittal

Charges or claims are dismissed, or the accused is found not guilty.

Seeds of Vice preserves these distinctions because institutional accountability requires accuracy in both directions.

Government allegations should not be minimized.

They also should not be upgraded into findings that were never made.

Practical Consequences for Registrants

A DEA registration matter can result in:

No action
Education
Technical correction
Additional documentation
Corrective-action requirements
A memorandum of agreement
Civil penalties
Restrictions on schedules or activities
Voluntary surrender
An order to show cause
Immediate suspension
Revocation
Criminal referral
Criminal prosecution

The public record does not reveal how often the St. Louis Division uses each outcome.

That omission makes it difficult to determine whether the regional program operates primarily through:

Compliance assistance
Negotiated correction
Administrative restriction
Punitive enforcement
Criminal referral

The cases publicly announced are generally the most serious or newsworthy.

Routine compliance work is less visible.

Practical Consequences for Patients

Patients are ordinarily not the direct targets of registration enforcement.

They may nevertheless experience its effects.

Legitimate Benefits

Diversion-control action may:

Stop forged prescriptions
Detect stolen medication
Remove impaired personnel from drug access
Correct unsafe pharmacy practices
Prevent unlawful prescribing
Improve institutional controls
Protect patients from substituted or diluted medication
Prevent stolen pharmaceuticals from entering illicit markets

Possible Adverse Consequences

An action may also contribute to:

Loss of a prescriber
Clinic closure
Pharmacy refusal
Delayed refills
Longer travel
Difficulty transferring records
Abrupt treatment interruption
Reduced willingness among clinicians to accept complex patients
Emergency-department use
Loss of local treatment in rural communities

The existence of these possible consequences does not establish that every DEA action causes patient harm.

It establishes why patient outcomes should be measured.

Rural and Regional Effects

The St. Louis Division’s geography includes areas where healthcare alternatives may be limited.

A patient in metropolitan St. Louis or Kansas City may have access to multiple hospitals, pharmacies, specialists, and transportation routes.

A patient in:

Western Kansas
Rural Missouri
The Ozarks
Southern Illinois

may have few nearby alternatives.

When a sole local prescriber, pharmacy, hospital, or treatment program loses controlled-substance authority, the practical effect may be greater than the same action in a dense metropolitan market.

That is a geographic inference.

It is not an allegation that DEA applies different legal standards in rural areas.

It means equal enforcement decisions can produce unequal access consequences.

Public Contact Information

St. Louis Division Headquarters

317 South 16th Street
St. Louis, Missouri 63103

Main telephone: (314) 538-4600

Media Inquiries

Telephone: (571) 362-5149

Community Outreach

Dan Plumb

Telephone: (571) 362-7591
Email: STLDiv.PublicAffairs@dea.gov

Recruitment

Special Agent Chris Most

Telephone: (314) 538-4600
Email: StLouisSpecialAgentRecruiter@dea.gov

Diversion Outreach

Telephone: (571) 387-5067
Email: StLouisDiversionOutreach@dea.gov

The public page does not describe the Diversion Outreach contact as:

A patient-complaint office
A direct enforcement line
A local investigator’s telephone
An administrative-hearing office
A guarantee of immediate registration assistance

People should identify the nature of their inquiry clearly and verify current submission instructions before transmitting confidential records.

Seeds of Vice Analysis

The following is Seeds of Vice analysis.

It is not an official DEA statement.

The Division’s First Accountability Problem Is Its Own Boundary

The St. Louis Division’s public record begins with an unresolved geographic contradiction.

One live DEA page says the division serves all Illinois.

Current leadership materials say southern Illinois.

The Chicago Division simultaneously states that it serves Illinois.

This may be a website-labeling problem rather than an operational failure. But the public should not have to infer the jurisdiction of a federal field division from office geography and conflicting headings.

A national law-enforcement agency should publish:

Exact state coverage
County-level boundary maps where states are divided
Which office handles each county
Which division receives registration and diversion inquiries
How overlapping metropolitan or judicial areas are administered

Jurisdiction is basic public information.

The Ten-Office Structure Is Visible; Diversion Placement Is Not

DEA identifies ten regional offices.

It does not identify which contain diversion personnel.

That prevents the public from knowing whether:

Diversion Investigators are distributed across the territory
Diversion work is centralized in St. Louis
Kansas has its own diversion supervisory structure
Southern Illinois matters are handled locally
Rural registrants must rely on distant personnel
Registration and enforcement work are housed in the same locations

An office map without functional assignments shows presence, not structure.

Transparency Is Strongest at the Top

The public can readily identify:

Steven L. Hofer
His professional background
The headquarters
The field locations
General outreach contacts

The structure becomes less visible below the Special Agent in Charge.

The public cannot readily identify:

The current Diversion Program Manager
Diversion supervisors
State assignments
Investigator distribution
Regulatory workload
Registration delays
Inspection outcomes
Administrative-action totals
Patient-access effects

The last publicly named regional Diversion Program Manager located in official materials was identified in 2024.

The current 2026 page supplies only a generic diversion contact.

That is a meaningful transparency gap.

Selected Cases Cannot Demonstrate Overall Performance

The representative matters show that diversion oversight can address serious misconduct.

They do not reveal whether the overall system is:

Proportionate
Consistent
Timely
Educational
Punitive
Effective
Protective of legitimate supply

A regulatory program cannot be evaluated solely from the cases it chooses to announce.

The public also needs to know:

How many registrants comply
How many problems are corrected
How many allegations are unsupported
How long cases remain unresolved
How many registrations are delayed
How many patients are displaced
Whether lawful access remains adequate

Enforcement visibility is not the same as institutional accountability.

State Prescribing Data Are Not Division Performance Data

Missouri, Kansas, and Illinois prescribing rates are shaped by many institutions.

They are not controlled exclusively by the DEA St. Louis Division.

Influences include:

State law
State licensing boards
Prescription-monitoring programs
Federal law
Insurers
Hospitals
Pharmacy chains
Manufacturers and distributors
Clinical guidance
Supply conditions
Prescriber judgment
Patient demographics
Disease and injury prevalence

A decline in state prescribing does not prove that the regional DEA office caused the decline.

It also does not prove that all reductions were medically beneficial.

The proper inquiry is not merely whether prescribing decreased.

It is whether:

Diversion decreased
Unsafe prescribing decreased
Legitimate treatment remained available
Patient outcomes improved
Rural access was preserved
Clinicians could still exercise individualized judgment

Those are separate questions.

Missouri’s Data Restrictions Complicate Regional Oversight

Missouri’s statewide PDMP limits interstate sharing and restricts law-enforcement access.

That is a state policy choice.

It means the St. Louis Division operates across three states without one automatically unified prescription database.

This can protect confidentiality and limit generalized law-enforcement access.

It may also require different legal processes and investigative methods in each state.

The division should publicly explain, at a general level:

How it lawfully obtains state PDMP information
What legal process is required
Who may authorize access
How searches are audited
How inaccurate data are corrected
How raw volume is prevented from becoming a substitute for evidence

These disclosures need not reveal active investigative techniques.

Access Must Be Measured Alongside Enforcement

DEA’s stated mission already requires legitimate supply to remain adequate and uninterrupted.

The division therefore should be capable of reporting not only what it removed or restricted, but what remained available.

That does not require DEA to guarantee every prescription.

It requires the agency to evaluate whether its interventions produce foreseeable access failures.

The relevant questions include:

Was another practitioner available?
Were patients notified?
Were records transferred?
Did the pharmacy remain open?
Did the community retain another controlled-substance provider?
Were cancer, hospice, surgical, addiction-treatment, and chronic-pain patients considered?
Did a rural action create a treatment desert?
Was legitimate supply interrupted?

A system that counts surrendered registrations but does not count displaced patients measures only one side of its own mission.

The Central Question

The St. Louis Division has participated in legitimate cases involving:

Forgery
Registration misuse
Unlawful prescribing
Pharmacy noncompliance
Institutional failures
Theft

The central accountability question is not whether those cases should exist.

It is whether the division can demonstrate, with equal seriousness, that it:

Distinguishes misconduct from medical complexity
Uses proportionate remedies
Corrects technical problems where correction is sufficient
Protects due process
Preserves lawful access
Measures unintended consequences
Publishes enough information for the public to evaluate the system

DEA’s own mission provides the standard.

Recommended Public Disclosures

Seeds of Vice recommends that DEA publish an annual St. Louis Division diversion-control report.

Jurisdiction

The report should identify:

The exact Illinois counties within the division
The boundary with the Chicago Division
The office responsible for each county
Procedures for matters crossing division boundaries
Whether separate boundaries apply to enforcement and registration work

Personnel and Structure

DEA should disclose:

The current Diversion Program Manager
The regional diversion organizational chart
Supervisory responsibility by state
Office classification for each location
Offices containing Diversion Investigators
Number of diversion personnel by state
Vacant supervisory positions
Public-facing registration contacts

Registration

The report should include:

Active registrants by state
Registrants by category
New applications
Renewals
Modifications
Denials
Withdrawals
Average processing times
Pending applications
Applications delayed beyond established targets
Reasons for material delays

Compliance

DEA should report:

Regulatory inspections
Registrants found compliant
Technical deficiencies
Corrective letters
Follow-up inspections
Memoranda of agreement
Compliance conferences
Voluntary corrective actions
Matters closed without formal enforcement

Enforcement

The report should distinguish:

Administrative subpoenas
Inspection warrants
Search warrants
Civil settlements
Civil penalties
Voluntary surrenders
Orders to show cause
Immediate suspension orders
Registration restrictions
Revocations
Criminal referrals
Criminal charges
Guilty pleas
Convictions
Acquittals
Dismissals
Government withdrawals

Theft and Loss

DEA should disclose:

Theft-and-loss reports received
Registrant categories involved
Substances and quantities
Employee-diversion matters
Outside burglaries
Average reporting delays
Average closure times
Institutional corrective actions
Matters determined not to involve diversion

State Data Use

DEA should explain:

How Kansas K-TRACS information is obtained
How Missouri PDMP restrictions are observed
How Illinois PMP information is obtained
Whether administrative subpoenas are required
Access-audit procedures
Data-retention practices
Correction procedures
Interstate data limitations
Safeguards against treating prescribing volume as proof

Patient and Community Effects

The report should measure:

Patients potentially affected by registration action
Advance-notice procedures
Record-transfer arrangements
Referral coordination
Rural-access consequences
Hospital and pharmacy continuity
Treatment-program continuity
Complaints involving abrupt discontinuation
Whether alternate providers were available
Whether legitimate supply remained adequate

These disclosures can be aggregated and anonymized.

They need not reveal confidential patient information, investigative techniques, or protected personnel information.

Methodology and Evidentiary Limits

This page was fully reviewed through July 25, 2026.

Priority was given to:

DEA
DEA Diversion Control
United States Department of Justice
Centers for Disease Control and Prevention
Kansas state agencies
Missouri state agencies
Illinois state agencies

The following rules were applied:

Current personnel are identified only through current official sources.
Historical personnel are not silently presented as current officials.
The current Special Agent in Charge is distinguished from the prior SAC.
Kimberly Daniels is identified only according to her last verified public role.
The St. Louis Field Division is distinguished from the national Diversion Control Division.
DEA’s conflicting Illinois descriptions are preserved rather than silently reconciled.
No county boundary is invented.
Office classifications are not inferred where DEA does not clearly provide them.
Broader narcotics enforcement is separated from diversion-control work.
Allegations, indictments, settlements, guilty pleas, convictions, sentences, administrative actions, and registration surrenders are treated as different legal events.
Press releases are treated as selected case records rather than comprehensive statistics.
Missouri, Kansas, and Illinois prescribing data are treated as state context—not St. Louis Division performance data.
Statewide Illinois data are not assigned exclusively to the St. Louis Division.
Prescription counts, MME measurements, patient percentages, overdose deaths, and drug seizures are not merged into one statistical series.
Missing historical years are not interpolated.
No causal claim is made solely because enforcement, prescribing, and overdose trends overlap in time.
Possible patient consequences are identified as possible effects or reasoned inferences unless direct evidence establishes them.
Seeds of Vice analysis is separated from the official record.

The public record establishes that the St. Louis Division is a substantial regional federal command with ten offices across Missouri, Kansas, and southern Illinois.

It does not yet provide the information required to measure its complete diversion-control workload, establish its exact Illinois boundary, examine the proportionality of its interventions, or determine whether it consistently fulfills the lawful-access side of DEA’s stated mission.